Fresenius Medical Care is set to expand access to High-Volume Hemodiafiltration (HighVolumeHDF) across seven out of 10 centres in Mexico.
In partnership with the Coordination of National Institutes of Health and Specialty Hospitals (CCINSHAE), the initiative aims to provide low-income patients with advanced haemodialysis therapies.
Fresenius Medical Care Mexico and CCINSHAE have signed a two-year contract to install the Fresenius Medical Care 5008S CorDiax technology in renal treatment centres in Mexico City and its metropolitan area.
A total of 150 systems will be deployed, offering standard hemodialysis and HighVolumeHDF, which has been shown to improve patient well-being and cost-effectiveness.
Fresenius Medical Mexico care enablement commercial operations managing director Edgar Robles said: “The groundbreaking pilot program, with its mission to provide chronic kidney disease patients with access to high quality treatments that were previously out of their reach, represents an important advancement in CKD in Mexico.”
“Fresenius Medical Care is committed to providing access to innovative therapies such as HighVolumeHDF.
“Our approach is to raise quality standards in dialysis, which also improves the quality of life of patients and simplifies operational procedures and provides efficient haemodialysis solutions for healthcare professionals.”
The collaboration has already enabled 240 new CCINSHAE patients, lacking public or private medical coverage, to receive HighVolumeHDF treatment.
Also, 410 regular patients with insurance have begun receiving the therapy since last year.
Some transitioned from the haemodialysis programme, while others were new patients due to various reasons, including new diagnoses or transitions from peritoneal dialysis.
High-Volume Hemodiafiltration is supported by clinical studies such as the CONVINCE1 Trial, which showed a 23% reduction in all-cause mortality for patients treated with HighVolumeHDF compared to standard high-flux haemodialysis.
The therapy is currently available in several countries across the Americas, including Argentina, Brazil, Canada, and Mexico.
Fresenius Medical Care plans to introduce HighVolumeHDF therapy to the US market.
The company received the US Food and Drug Administration (FDA) 510(k) approval for its 5008X Hemodialysis System in February last year.
The updated 5008X CAREsystem also received FDA clearance by May this year, facilitating broader commercialisation efforts in the US, with a full-scale launch anticipated in 2026.
